Retrospective Study and Construction of a Prediction Model for Patients With Intermediate and Advanced Liver Cancer Treated With TACE Combined With Immunotherapy and Targeted Therapy
Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY
To evaluate the effectiveness of TACE combined with immunotherapy and targeted therapy versus TACE alone in patients with intermediate and advanced liver cancer.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
View:
• ≥18 years old, both men and women
• primary liver cancer confirmed by liver biopsy or history of hepatitis B, AFP, and typical imaging findings
• patients with liver function Child-Pugh A or B (≤8 points)
• BCLC stage B and stage C
• expected survival time ≥8 weeks
• patients with generally good performance status (ECOG PS score 0 or 1)
Locations
Other Locations
China
the Qianfoshan Hospital
RECRUITING
Jinan
Contact Information
Primary
Jing Liang, Dr
liangjing0531@163.com
0086-18663761275
Time Frame
Start Date: 2024-01-01
Estimated Completion Date: 2024-12
Participants
Target number of participants: 100
Treatments
TACE+PD-(L)1+TKI
Application of TACE, TKI, and immunotherapy in patients with intermediate and advanced liver cancer.
TACE alone
Application of TACE in patients with intermediate and advanced liver cancer.
Related Therapeutic Areas
Sponsors
Leads: Qianfoshan Hospital